Promoters of generics-maker Cipla Ltd. plan to sell up to 2.53% stake in the company via open market transactions on Wednesday. The price range has been set at Rs 1,289.5-1,357.35 apiece, Bloomberg News reported, citing the termsheet.
The amount aggregates to $316 million, or around Rs 2,638 crore. Kotak Securities is the broker for the sale.
The Hameid family has 33.47% equity as of March, majorly held by billionaire Yusuf Khwaja Hameid (18.68%).
Cipla's profit rose 79% year-on-year to Rs 931.9 crore in the quarter-ended March. Analysts tracked by Bloomberg had a consensus estimate of Rs 868 crore. Revenue advanced 7.4% to Rs 6,163.2 crore.
Revenue of the company's South Africa business rose by 26% in local currency terms, while that in North America and India markets grew by 11% and 7%, respectively.
The company's R&D investments stand at Rs 444 crore or 7.2% of sales, higher by 19% YoY, driven by product filings and developmental efforts.
The drugmaker also declared a final dividend of Rs 13 per equity share for financial year 2024.
RECOMMENDED FOR YOU
Cipla Recalls Over 20,000 Packs Of Inhalation Drug In US
Aug 27, 2025
Jharkhand Failed To Submit Utilisation Certificates For Rs 1.33 Lakh Crore Grants: CAG Report
Aug 25, 2025
'Add' Cipla Shares, Maintains Dolat Capital Post Q1 Results — Check Target Price
Jul 28, 2025
Cipla Share Price Trades Lower Post Q1 Results
Jul 28, 2025
POPULAR